TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00005113

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: dosage is in oral form titrated to target trough level

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: dosage is in oral form titrated to target trough level
Study: NCT00219687

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dispatcher-assisted CPR with compressions & ventilations
Description: Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dispatcher-assisted CPR instructions with compressions only
Description: Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
Study: NCT04197232

Intervention type: OTHER
Intervention: clinical evaluation
Description: - In children: general clinical evaluation, birth weight, APGAR, ECG, admission to ICU, hospital admissions in perinatal age, presence of malformations; complete blood count, inflammatory index, complement, antibiotic treatment, brain ultra-sound, presence of infection, presence of sepsis, presence of necrotizing enterocolitis, growth curve, presence of recurrent infections, developmental milestones, response to vaccines, admission to hospital in the first year of life.
Study: NCT04277130

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention with active video games
Description: Participants in intervention group were paired up by their teachers. Each participant had a classmate playing with him/her, and the waiting time is minimal because Xbox 360 Kinect allowed double play mode. The intervention group was provided with an AVG, the Xbox 360 Kinect technology (Kinect Sports Seasons I \& II, including bowling, soccer, boxing, track and field, table tennis, beach volleyball, golf, tennis). The AVG intervention consisted of two 30-min sessions per week, for a total of 12 weeks. Participants either played in PE classes and/or recess. They had no other specific routing of activities but straight played the AVG during the intervention. They could free to choose games they like in the Xbox 360. The AVGs of Xbox 360 chosen was of moderate to vigorous intensity (3-6 METs) and no matter what games they chose, their PA level would be between moderate and vigorous intensity.
Study: NCT00427557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 by vein for 4 Days (Day -10 through Day -7).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: 140 mg/m\^2 by vein for 1 Day (Day -7).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Blood
Description: 1 UCB Unit by vein on Day -5.
Study: NCT02695836

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Face-to-face support workshops
Description: On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: On-demand email and telephone support
Description: Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
Study: NCT00427557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Infusion
Description: Infusion of blood stem cells on Day 0.
Study: NCT03982199

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: RSV Vaccine
Description: Participants will receive a single IM injection of an Ad26-based RSV vaccine at a single dose level on Day 1 and revaccination after either 1 year, 2 years, or 3 years.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a single IM injection of placebo control on Day 1.
Study: NCT02757885

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Transplant (BMT)
Description: Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) mismatched donor through a central venous catheter.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Description: Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing \>125% ideal body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing \>125% ideal body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine monophosphate
Description: Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing \> 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.~Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.~For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rabbit Anti-thymocyte Globulin
Description: Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Participants will receive 200 cGy of TBI in a single fraction.
Study: NCT01775345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isotonic exercises
Description: 20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.~Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isokinetic exercises
Description: 20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Isotonic and isokinetic exercises
Description: 20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST
Description: Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
Study: NCT03082261

Intervention type: DEVICE
Group type: OTHER
Intervention: Prodigy, Prodigy MRI or Proclaim Elite IPG
Description: Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
Study: NCT00494299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib (Nexavar, BAY43-9006)
Description: Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo: matching placebo
Study: NCT02051842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metadoxine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metadoxine
Study: NCT03333304

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Procalcitonin measurement
Description: Discontinuation of antimicrobials according to Procalcitonin Kinetics
Study: NCT03580967

Intervention type: DRUG
Group type: OTHER
Intervention: Vortioxetine
Description: Oral pill to be taken daily for 8 weeks, 10 or 20 mg dosage. Participants who cannot tolerate this dose may be reduced to 5mg dose.
Study: NCT00358423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegaptanib Sodium
Description: 0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Sham injections, every 6 weeks, up to a total of 3 sham injections
Study: NCT04689321

Intervention type: OTHER
Intervention: No intervention
Description: This is not an interventional study.

Intervention type: OTHER
Intervention: No intervention
Description: This is not an interventional study.
Study: NCT03778593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: D1-2 5-Fluorouracil 1000 mg/m2 + 5DW 1L continuous IV over 23 hours q 2 weeks
Study: NCT03998566

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TraceIT Tissue Spacer implantation
Description: The TraceIT Tissue Spacer will be implanted between duodenum and pancreas using endoscopic procedure. After implantation patient will have radiotherapy treatment per standard of care.
Study: NCT05406648

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Morus nigra concentrate
Description: The experimental group was given 20 grams of black mulberry (morus nigra) concentrate per day for 12 weeks.
Study: NCT02654847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Study: NCT04476186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir
Description: oral syrp

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KOH 10 %
Description: solution for local application
Study: NCT03843515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Neoadjuvant nivolumab flat dose 400mg
Study: NCT02807441

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Patients will receive different doses of aspirin perioperatively to assess bleeding association.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid
Description: Patients will receive different doses of aspirin perioperatively to assess bleeding association.
Study: NCT03778593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: D1 Leucovorin 400 mg/m2 + 5DW 200 ml mix IV over 2 hours q 2 weeks
Study: NCT03594825

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Different time of taking medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Different time of taking medicine
Study: NCT03778593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: D1 Irinotecan 135 mg/m2 + 5DW 500 mL mix IV over 2 hours (concurrent with the leucovorin infusion) q 2weeks
Study: NCT01775345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST
Description: Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ST
Description: Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
Study: NCT01275157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2452473
Description: Administered orally as a liquid suspension
Study: NCT00203606

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated interferon alfa-2a ( Roche) and ribavirin
Description: pegylated interferon alfa-2a ( Roche) and ribavirin
Study: NCT02845414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CD133KDEL (dCD133KDEL)
Description: Patients will receive dCD133KDEL at the assigned dose level via a 30-minute intravenous infusion on days 1, 3, 5, 8, 10 and 12 (total of 6 doses) of a 28-day cycle.
Study: NCT02654847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution, used as a diluent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution, used as a diluent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution, used as a diluent.
Study: NCT03575520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: A fixed dose of 6.0 mg pegteograstim was administered subcutaneously on day 2 of each chemotherapy cycle (between 22 and 26 hours after the completion of chemotherapy).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin/Cyclophosphamide(AC) treatment
Description: doxorubicin 60mg/m2 IV every 2 weeks cyclophosphamide 600mg/m2 IV every 2 weeks~Four cycles of dose dense AC treatment will be given every 2 weeks.
Study: NCT03552029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: 20 or 30 mg tablets for oral administration
Study: NCT02249234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01599468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline serum
Description: The Placebo group received normal saline with the same volumes
Study: NCT03161769

Intervention type: PROCEDURE
Intervention: Neurovascular treatment of intracranial aneurysms
Description: Endovascular treatment of intracranial aneurysms using flow diverting stents

Intervention type: DEVICE
Intervention: AneurysmFlow image processing software
Description: Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
Study: NCT03778593

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: D1 Oxaliplatin 65 mg/m2 + 5DW 200 mL mix IV over 2 hours q 2 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% dextrose water
Description: mix fluid with 5-FU, leucovorin, irinotecan, and oxaliplatin
Study: NCT03359031

Intervention type: OTHER
Group type: OTHER
Intervention: Patient education
Description: This group will be given a pamphlet on pain control, narcotic medication, and compartment syndrome including its pathophysiology, signs/symptoms, and treatment.
Study: NCT02654847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution, used as a diluent.
Study: NCT03552029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quizartinib
Description: 20 or 30 mg tablets for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: 5, 20, 80 or 200 mg capsules for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: 5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: 5, 20, 80 or 200 mg capsules for oral administration; 30, 45, 80, or 100 mg capsules may be utilized
Study: NCT00470626

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Celect Vena Cava Filter
Description: Effective filtration of inferior vena cava blood to prevent thromboembolism.
Study: NCT03239925

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Electromagnetic field of cell phone in ''on'' mode.
Description: In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.

Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Electromagnetic field of cell phone in 'off' mode.
Description: In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
Study: NCT00777556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-104
Description: One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
Study: NCT03838796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenvatinib
Description: for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po
Study: NCT02654847

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution, used as a diluent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Normal Saline
Description: 0.9% sodium chloride solution, used as a diluent.
Study: NCT04299542

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous lung biopsy using conventional MDCT
Description: Conventional CT biopsy will be performed using a 64 slice CT scanner. A preliminary plain CT is acquired covering the entire target lesion with a skin marker, and the interventional radiologist would decide on the skin puncture site and the needle pathway. A post-procedural CT scan will be made to detect pneumothorax or pulmonary haemorrhage. All images will be archived in the picture achieving and communication system (PACS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous lung biopsy CBCT
Description: CBCT guided biopsy will be performed in the angiography suite. A preliminary CBCT (DynaCT) is acquired covering the entire target lesion is first performed. Image data will be displayed and processed using Syngo iGuide system. A potential needle trajectory will be drawn from skin to lesion. Integration of the cross-sectional images and real time fluoroscopy will result in three system positions: one bull's eye view and two progression views. During fluoroscopy, the planned needle trajectory and target will be overlaid on the real time fluoroscopy image. After the needle reaches the target, another CBCT will be performed to confirm needle position. Biopsy using coaxial system and post-procedural CT scans will be performed in similar fashion as the conventional CT group.
Study: NCT00108173

Intervention type: DRUG
Group type: OTHER
Intervention: Zyban
Study: NCT03838796

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenvatinib
Description: for patients \<60kg, lenvatinib 8mg bid po for patients \>60kg, lenvatinib 12mg bid po

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TACE
Description: The patient underwent transfemoral hepatic artery angiography one month after surgery to observe whether there was tumor staining in the liver. If there was suspicious tumor staining, micro-catheter was superselected to the tumor blood vessel, the embolization agents and chemotherapy drugs were injected. If there was no tumor staining, a small amount of embolization agents were slowly injected into the artery.
Study: NCT02721225

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructooligosaccharide
Description: A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health
Study: NCT02976792

Intervention type: PROCEDURE
Intervention: Renal Resistive Index/NephroCheck™test
Description: Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI